BELS Summit, London

A New Vantage for the Health & Life Sciences in a Post-Brexit World
Day 1 hosted by Simmons & Simmons  ▪   Day 2 hosted by Bloomberg

Regrettably, in light of the lack of progress in Brexit negotiations, we have taken a decision to postpone BELS 2017 Summit – A New Vantage for the Health & Life Sciences in a Post-Brexit World.

While we continue to believe the Summit represents a unique and ground-breaking event, our plan for the December 4-5, 2017 meeting was to update everyone on some great UK assets and to paint a rough post-Brexit picture of our sector.  However, we seem to be stuck in a vortex of political posturing, in terms of both the EU-UK negotiations and internally within the UK parties.  Absent any clarity, the rationale (and motivation) for the Summit has become premature for our global guests at this time.  When there is some certainty about the realistic impact of Brexit and how our sector will function in a post-Brexit world, we will come back to everyone with new dates in 2018.

Several of the UK’s top leadership were keen to address the Summit, including a government minister; leadership of NICE, the MHRA, MRC, the Clinical Research Network, UK BioBank, and Health Data Research UK; plus senior officials and academics from Innovate UK, Oxford University, Genomics England, etc.  We hope that you, these other UK leaders, and the many others who had intended to participate in the December Summit will remain keen to be involved when the timing is better for this meeting.

In the meantime, BELS will continue:

  • Sending out news of the UK to the many loyal and avid overseas readers of BELS Brief Clips
  • Progressing specific projects to encourage and enable greater collaboration and impact
  • Building awareness of interesting UK initiatives
  • Expanding the overall BELS community beyond its current 3,000 (we’d welcome your referrals)

We will update all regarding the timing of, support for and potential of the Summit in 2018.

Sponsorships are available. Please contact us for details.

The UK is creating the right environment and culture where life science innovation is highly prioritised with government wrapping around it a system of incentives to energise it. Annalisa Jenkins, CEO, Dimension Therapeutics, Cambridge, MA

Feedback from BELS inaugural UK event in 2015

The Summit assembled a remarkable mix of people… We need to find new ways to talk to each other and work together. This has been a terrific way to start that dialogue.  Sir John Bell, the Regius Professor of Medicine at the University of Oxford, The Alumni Summit Chair

It was a terrific event. Great networking and I learned a tremendous amount. I would be very interested in participating more in future.   Dr Rupert Vessey, President, Research & Early Development, Celgene, USA

Maintain and develop this event.  Simon Russell, Chief Business Officer, Creabilis, Switzerland

Hold more of these events so that connections made may be strengthened. I found the idea that rather than competing with the USA in terms of therapeutic-focused biotechs the UK is instead focusing upon its strengths in the genetic technologies area. I found this both exciting and fascinating.  Simon Blake, Sr Director, Scientific Licensing for Immunology, Johnson & Johnson, USA

I was inspired to learn about ways in which the NHS sees itself as a catalyst for innovation.  Dr Ronald Farquhar, Biotech Investor, Morningside, USA

I was positively surprised at how much the UK was doing particularly in big data and healthcare records. The US has a lot to learn from these efforts.  Dr John Richards, VP Global Technical Development, The Medicines Company, USA

I really enjoyed the conference – I made some very helpful business connections.   Heather Preston, Managing Director, TPG Biotech, USA